Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for 10x Genomics Inc. (TXG:NASDAQ), powered by AI.
10x Genomics Inc. is currently trading at $20.21. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for 10x Genomics Inc. on Alpha Lenz.
10x Genomics Inc.'s P/E ratio is -64.2.
“10x Genomics Inc. trades at a P/E of -64.2 (undervalued) with modest ROE of -5.8%.”
Ask for details →10x Genomics Inc. is a biotechnology company known for developing advanced genomic analysis technologies designed to power breakthroughs in biological research. The primary purpose of 10x Genomics is to enhance the understanding of complex biological systems by providing tools that offer insights into cellular and molecular structures at unprecedented resolutions. The company's products include innovative single-cell and spatial gene expression platforms, which are instrumental in studying genetic variations, gene expression, and complex biological phenomena across numerous sectors. Notable for its impact on life sciences and healthcare industries, 10x Genomics serves researchers in fields such as oncology, immunology, and neuroscience, among others, enabling them to explore genetic foundations of health and disease more deeply. Headquartered in Pleasanton, California, 10x Genomics plays a significant role in facilitating scientific advancements and accelerates discovery in translational and clinical research settings, contributing to the broader pursuit of personalized medicine and novel therapeutic strategies.
“10x Genomics Inc. trades at a P/E of -64.2 (undervalued) with modest ROE of -5.8%.”
Ask for details →10x Genomics Inc. (ticker: TXG) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 1,306 employees. Market cap is $2.8B.
The current price is $20.21 with a P/E ratio of -64.23x and P/B of 3.51x.
ROE is -5.78% and operating margin is -17.25%. Annual revenue is $643M.